3 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 20 points (-0.2%) at 12,795 as of Monday, Nov. 12, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,283 issues advancing vs. 1,555 declining with 129 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.1%. A company within the sector that fell today was Express Scripts ( ESRX), up 0.8%. A company within the sector that increased today was Baxter International ( BAX), up 1.0%.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector lower today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $1.76 (-1.1%) to $154.76 on average volume Thus far, 198,876 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 424,400 shares. The stock has ranged in price between $154.69-$156.93 after having opened the day at $156.63 as compared to the previous trading day's close of $156.53.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $92.7 billion and is part of the drugs industry. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 38.6% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Novo Nordisk A/S Ratings Report now.

2. As of noon trading, GlaxoSmithKline ( GSK) is down $0.47 (-1.1%) to $43.08 on average volume Thus far, 1.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $42.50-$43.39 after having opened the day at $43.32 as compared to the previous trading day's close of $43.55.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $110.3 billion and is part of the drugs industry. The company has a P/E ratio of 13.2, below the S&P 500 P/E ratio of 17.7. Shares are down 4.3% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full GlaxoSmithKline Ratings Report now.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.17 (-0.5%) to $32.06 on light volume Thus far, 2.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.3 million shares. The stock has ranged in price between $32.01-$32.25 after having opened the day at $32.14 as compared to the previous trading day's close of $32.23.

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $53.0 billion and is part of the drugs industry. The company has a P/E ratio of 28.9, above the S&P 500 P/E ratio of 17.7. Shares are down 8.5% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Jim Cramer Just Spoke to Larry Kudlow About the China Trade Negotiations

Stocks Rise, Facebook Ignites a Nasdaq Rally

Stocks Rise, Facebook Ignites a Nasdaq Rally

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

Short Seller Chanos Slams Tesla's Musk, Accuses Him of 'Incinerating' Capital

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

AMD Shares Explode After Solid Q1, Robust Outlook That Defies Chip Sector Gloom

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts

Facebook Stock Set for Biggest Gain in Two Years After Q1 Earnings Top Forecasts